1. Aplastic anemia in a patient receiving felbamate for complex partial seizures
- Author
-
Robert L. Macdonald, Page B. Pennell, and Mohammed S. Ogaily
- Subjects
Pediatrics ,medicine.medical_specialty ,Neurology ,Complex partial seizures ,medicine.medical_treatment ,Phenylcarbamates ,Felbamate ,Central nervous system disease ,Food and drug administration ,Epilepsy, Complex Partial ,medicine ,Humans ,Aplastic anemia ,Chemotherapy ,business.industry ,Anemia, Aplastic ,Middle Aged ,medicine.disease ,Anticonvulsant ,Propylene Glycols ,Anesthesia ,Anticonvulsants ,Female ,Neurology (clinical) ,business ,medicine.drug - Abstract
Article abstract-A 53-year-old woman began taking felbamate for uncontrolled complex partial seizures. Four months later, she developed fatigue and ecchymotic skin lesions. Laboratory studies revealed very severe aplastic anemia. There have been an additional nine reported cases of aplastic anemia in the setting of felbamate treatment. The association between felbamate and aplastic anemia has resulted in a joint recommendation by the US Food and Drug Administration and the manufacturer of felbamate, Carter-Wallace, Inc., for the immediate withdrawal of patients from treatment with felbamate.NEUROLOGY 1995;45: 456-460
- Published
- 1995